Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom  by Bermingham, Sarah L. et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 0 0 – 8 0 91098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10
Conﬂict of intere
E-mail: s.l.bermi
* Address correspojournal homepage: www.elsevier .com/ locate / jva lCost-Effectiveness Analysis of Alternative Antiviral Strategies for
the Treatment of HBeAg-Positive and HBeAg-Negative Chronic
Hepatitis B in the United Kingdom
Sarah L. Bermingham, BSc, MSc1,*, Ralph Hughes, BSc, MSc2, Elisabetta Fenu, MPharm, MSc2,
Laura M. Sawyer, BSc, MSc3, Elizabeth Boxall, PhD, FRCPath, FFPH4,
Patrick T. Kennedy, MB, BCH, BAO, BMedSci, MRCP, MD5, Geoff Dusheiko, MD, MB, BCh6,
Grant Hill-Cawthorne, MA, MB, BChir, MRCP7, Howard Thomas, BSc, MB, PhD, FRCP8
1Symmetron Limited, Toronto, Ontario, Canada; 2Royal College of Physicians, National Clinical Guideline Centre, London, UK;
3Symmetron Limited, Borehamwood, UK; 4Virology Laboratory, Health Protection Agency, Microbiology Services Division, Heartlands
Hospital, Birmingham, UK; 5Barts and The London School of Medicine and Dentistry, London, UK; 6UCL Institute of Liver and
Digestive Health, Royal Free Hospital, London, UK; 7Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney School of
Public Health, University of Sydney, Sydney, Australia; 8Section of Hepatology and Gastroenterology, Department of Medicine,
Imperial College, London, UKA B S T R A C TBackground: Seven drugs are licensed for the treatment of chronic
hepatitis B (CHB) in the United Kingdom. Which initial treatment,
secondary therapy, and whether antivirals should be given alone or in
combination are questions of considerable uncertainty. Objective:
The aim of this model was to undertake a comprehensive economic
evaluation of all antiviral treatments for CHB to recommend the most
cost-effective therapeutic sequence. Methods: We developed a prob-
abilistic Markov model to compare the cost-effectiveness of all
clinically relevant antiviral treatment sequences for nucleos(t)ide-
naive adults with hepatitis B e-antigen (HBeAg)-positive or HBeAg-
negative CHB. Relative rates of HBeAg seroconversion and viral
suppression were obtained from a network meta-analysis. Data on
mortality, antiviral drug resistance, durability of response, adverse
events, and costs were obtained from published literature. Results are
reported in terms of lifetime costs, quality-adjusted life-years
(QALYs), and expected net beneﬁt. Results: In the base-case analysis,
pegylated interferon alpha-2a (peg-IFN α-2a) followed by tenofoviree front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.05.007
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ndence to: Sarah L. Bermingham, Symmetron Limdisoproxil fumarate was most effective and cost-effective in HBeAg-
positive patients, with a cost of £7488 per QALY gained compared with
no treatment. In HBeAg-negative patients, peg-IFN α-2a followed by
entecavir was most effective and cost-effective, with a cost of £6981
per QALY gained. The model was robust to a wide range of sensitivity
analyses. Conclusions: Peg-IFN α-2a followed by tenofovir disoproxil
fumarate or entecavir is the most effective antiviral treatment
strategy for people with both variants of CHB. At a cost of less than
£10,000 per QALY gained, these sequences are considered cost-
effective in England and Wales. The results of this analysis were used
to inform 2013 National Institute for Health and Care Excellence
guideline recommendations.
Keywords: antiviral treatment, chronic hepatitis B, cost-effectiveness
analysis, interferon-alpha, nucleosides, nucleotides.
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Chronic hepatitis B (CHB) is an infectious disease that affects
approximately 400 million people worldwide [1]. The hepatitis B
virus (HBV) infects liver cells and may lead to an immune
response in which infected cells are killed but the virus is not
eliminated. Over time, this can lead to cirrhosis, hepatocellular
carcinoma (HCC), and death [1].
There are two molecular variants of HBV, which are deﬁned
according to the presence or absence of the hepatitis B “e”
antigen (HBeAg). Over the course of infection, HBeAg-negative
CHB may arise because of the selection of precore or other HBVmutant strains affecting the expression of HBeAg [2]. This variant
is more frequently observed in older patients and is associated
with worse outcomes than HBeAg-positive CHB [3].
Currently, seven drugs are licensed for the treatment of adults
with CHB. Interferon-alpha (IFN-α) and pegylated interferon
alpha-2a (peg-IFN α-2a) are injected subcutaneously, whereas
nucleosides (lamivudine [LAM], entecavir [ETV], and telbivudine)
and nucleotides (adefovir [ADV] and tenofovir [TDF]) are admin-
istered orally.
Interferon ampliﬁes the immune response with the aim
of achieving seroconversion and is administered over a 24- or
48-week course. Nucleos(t)ide analogues (NAs) inhibit viralociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 0 0 – 8 0 9 801replication and must be continued long-term. Although inter-
feron may reduce the probability of requiring NA treatment, it
is costly and associated with signiﬁcant adverse effects. NAs
are associated with relatively few adverse outcomes, but the
effectiveness of some drugs is limited by high rates of antiviral
resistance.
Patients may receive treatment of ﬁnite duration with IFN-α or
peg-IFN α-2a before starting NA therapy, or they may initiate a
long-term course of NA treatment de novo. If patients develop
resistance to an NA, they may be switched to a complementary
“rescue therapy” with a drug that does not share cross-resistance.
Alternatively, they may receive “add-on” therapy as a means of
controlling multidrug resistance.
The choice of initial therapy, rescue therapy, and whether
rescue therapy should be given alone or in combination are
issues of considerable uncertainty. Several economic evalua-
tions have considered parts of this question in isolation, but
none has simultaneously assessed all available alternatives in
both HBeAg-positive and HBeAg-negative populations [4]. The
aim of this model was to undertake a comprehensive economic
evaluation of all antiviral treatments for CHB to recommend the
most cost-effective therapeutic sequence. This model was
developed by the guideline development group (GDG) of the
2013 National Institute for Health and Care Excellence (NICE)
guideline Diagnosis and Management of Chronic Hepatitis B in
Children, Young People and Adults [5]. The results of this
analysis were used to inform recommendations within the
guideline.Methods
Model Overview
We developed a probabilistic Markov cohort model using TreeAge
2009 to estimate lifetime costs in 2011 British pounds andFig. 1 – Natural history of CHB. A Markov model was developed t
changes on long-term outcomes in patients with either HBeAg-
transitions between health states may occur at each cycle. Circu
sum of all other transition probabilities from that health state). A
in each health state (not shown). (Color version of ﬁgure is avaiquality-adjusted life-years (QALYs) from a UK National Health
Service (NHS) and personal social services perspective. Costs and
QALYs were discounted at the standard annual rate of 3.5% [6].
Total net beneﬁt (NB) was used to rank order the cost-
effectiveness of each antiviral treatment strategy.
Figure 1 illustrates the key health states used to represent
the natural history of CHB and possible transitions between
them. Baseline population characteristics and baseline transi-
tion probabilities are reported in Table 1. The model structure
and baseline transition probabilities were informed by our
review of previously published CHB models [7–9]. Structural
decisions and probability estimates were discussed with clinical
experts from the GDG to ensure that the assumptions and
choice of data were directly relevant to the United Kingdom
(see Appendix Tables 4 and 5 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2015.05.007). Relative esti-
mates of effectiveness are reported in Table 1 and described
below.
Patients entered the model as NA-naive adults with either
HBeAg-positive or HBeAg-negative CHB. Approximately one-
ﬁfth of HBeAg-positive patients had evidence of active cirrhosis
at baseline, compared with one-third of the HBeAg-negative
population [12]; the remaining patients had active CHB that
required treatment. Active CHB was deﬁned as the presence of
HB surface antigen (HBsAg) for at least 6 months and HBV DNA
of more than 2000 IU/ml. Consistent with the epidemiological
literature, the average age at the start of treatment was 31
years for HBeAg-positive and 40 years for HBeAg-negative
patients [12]. Most of the patients in both populations were
male [12]. People coinfected with HIV and treatment-
experienced patients with LAM-resistant HBV were excluded
from the model.
At the end of each cycle, patients could remain in each health
state, achieve spontaneous or treatment-induced responses
(HBeAg seroconversion or viral suppression), or experience a
reactivation of the disease [17]. Patients could also developo extrapolate the impact of short-term serologic and virologic
positive or HBeAg-negative CHB. Linear arrows indicate
lar arrows indicate residual probabilities (i.e. one minus the
ll individuals were exposed to a background rate of mortality
lable online.)
Table 1 – Baseline population characteristics, transition probabilities, and relative effectiveness.
Model parameter Population
HBeAg-positive CHB HBeAg-negative CHB
Point
estimate
Range Source Point
estimate
Range Source*
Initial cohort characteristics
Age (y) 31 24–36 [10] 40 36–45 [10]
Male:female ratio 3.2 1.5–4.9 [10] 10.5 3.9–17 [10]
Compensated cirrhosis 17% 10%–24% [10] 35% 29%–38% [10]
Median serum HBV DNA (log10 copies/mL) 9.2 1.7–905 [10] 7.6 5.8–1756.8 [10]
Median serum ALT (IU/L) 143.4 83.0– 252.5 [10] 145.5 69.0–229.5 [10]
Natural history of CHB*
Active CHB to HBsAg seroconversion 1.8% 0.0%– 2.3% [7] 0.4% 0.2%–0.9% [10]
Active CHB to HBeAg seroconversion 10.7% 5.6%–17.7% [7] NA
HBeAg seroconversion to active CHB 0.5% 0.3%–0.9% [11] NA
HBeAg-positive CHB to HBeAg-negative CHB 5.0% 2.5%–7.5% [12] NA
Active CHB to undetectable HBV DNA 5.3% 2.7%–8.8% * 4.8% 1.2%–17.9% [13]
Undetectable HBV DNA to active CHB 12.5% 0.0%–28.7% [7] 12.5% 0.0%–28.7% [7]
Active CHB to HCC 0.5% 0.4%–0.6% [14] 0.5% 0.2%–1.5% [11]
Active CHB to CC 5.3% 2.3%–11.8% [12] NA
HBeAg seroconversion to HBsAg
seroconversion
0.7% 0.3%–1.3% [7] NA
HBeAg seroconversion to HBeAg-negative
CHB
2.8% 2.2%–3.5% [11] NA
HBeAg seroconversion to HCC 0.2% 0.1%–0.5% [11] NA
Undetectable HBV DNA to HBeAg
seroconverison
5.3% 2.7%–8.8% * NA
Undetectable HBV DNA to HBsAg
seroconversion
1.8% 0.0%–2.3% [7] NA
Undetectable HBV DNA to HCC 0.1% 0.0%–0.2% [14] 0.5% 0.2%–1.5% [7]*
Undetectable HBV to CC 1.6% 0.5%–3.4% [7]* 0.5% 0.0%–1.3% [7]
CC to HCC 2.3% 1.0%–4.4% * 2.3% 1.0%–4.4% [7]
*
CC to DC no treatment 5.0% 2.3%–9.5% [7] NA
CC to DC on treatment 1.4% 0.8%–2.0% [7] NA
DC to CC no treatment 0.0% 0.0%–0.0% [7] 0.0% 0.0%–0.0% [7]
DC to CC ﬁrst year on treatment 13.6% 10.5%–16.6% [7] NA
DC to HCC 2.9% 1.0%–6.3% * 2.9% 1.0%–6.3% [7]
*
DC to liver transplant 1.6% 0.0%–20.0% [15]* 1.6% 0.0%–20.0% *
HCC to liver transplant 1.6% 0.0%–3.1% [7]* 1.6% 0.0%–3.1% *
CC mortality 3.7% 3.0%–4.4% [10] 3.7% 3.0%–4.4% [10]
DC mortality 15.6% 11.9%–20.3% [10] 15.6% 11.9%–20.3% [10]
HCC mortality 56.0% 43.0%–99.0% [7] 56.0% 43.0%–99.0% [7]
LT mortality ﬁrst year 21.0% 6.0%–42.0% [16] 21.0% 6.0%– 42.0% [16]
LT mortality subsequent years 5.7% 2.0%– 11.0% [16] 5.7% 2.0%– 11.0% [16]
Relative risk of HBeAg seroconversion at 48 wk compared with placebo
LAM 2.35 2.04–2.66 [5] NA
ETV 2.43 1.83–3.57 [5] NA
TDF 2.70 2.21–2.66 [5] NA
Peg-IFN α-2a þ LAM 3.12 2.65–3.59 [5] NA
Peg-IFN α-2a 3.72 3.19–4.24 [5] NA
Relative risk of achieving undetectable HBV DNA at 48 wk compared with placebo
LAM 25.60 25.53–25.67 [5] 10.12 9.92–10.32 [5]
ETV 42.85 42.46–43.24 [5] 13.63 12.96–14.30 [5]
TDF 61.02 60.67–61.37 [5] 13.85 13.54–14.16 [5]
Peg-IFN α-2a þ LAM 79.09 76.06–82.12 [5] 30.97 29.97–31.97 [5]
Peg-IFN α-2a 84.72 81.50–87.94 [5] 29.45 26.63–32.27 [5]
ALT, alanine aminotransferase; CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; ETV, entecavir; HBV,
hepatitis B virus; IU, international units; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma;
LAM, lamivudine; LT, liver transplant; NA, not applicable; Peg-IFN α-2a, pegylated interferon alpha-2a; TDF, tenofovir.
* See Supplemental Material ﬁles found at http://dx.doi.org/10.1016/j.jval.2015.05.007 for a detailed calculation of each transition probability.
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Fig. 2 – Cost-effectiveness acceptability frontier. Abbreviations: Peg-IFN, pegylated interferon alpha 2a; LAM, lamivudine; ETV,
entecavir; TDF, tenofovir. (Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 0 0 – 8 0 9 803resistance to the active treatment, resulting in virologic break-
through and a change in treatment (not illustrated). A propor-
tion of patients with HBeAg-positive CHB could develop
HBeAg-negative CHB or transition from HBeAg seroconversion
to HBeAg-negative CHB. Patients who did not respond to
treatment entered progressive stages of liver disease such as
compensated or decompensated cirrhosis at rates that varied
according to viral load. They may remain in the compensated
stage or transition from decompensated to compensated cir-
rhosis spontaneously or as a result of treatment. People in
both decompensated cirrhosis and HCC health states were
considered eligible for liver transplant. Patients could develop
HCC or die at any stage of the model (see Figs. 1 and 2 in
Supplemental Materials found at: http://dx.doi.org/10.1016/j.
jval.2015.05.007).
The baseline risk of all-cause mortality was based on UK life
tables [18] multiplied by the standardized risk of mortality in
people with CHB reported by the REVEAL trial [19]. A mortality
risk in excess of baseline was applied to people with compen-
sated cirrhosis [10], decompensated cirrhosis [10], HCC [7], and
liver transplant [16].Comparators
Three key considerations inﬂuenced the selection of clinically
appropriate treatment alternatives:1. In the United Kingdom, LAM alone is no longer considered an
effective monotherapy based on extremely high rates of resist-
ance; however, it may be used in combination with other NAs.2. Resistance to LAM is known to confer cross-resistance to
other nucleosides that share the same site of action and
reduces sensitivity to ETV. When patients are treated sequen-
tially with drugs that have overlapping resistance proﬁles, the
second therapy is not only less effective but may also lead to
multidrug resistance [20].3. Certain combinations of drugs may cause renal toxicity when
used in combination (e.g., ADV and TDF).
To improve the efﬁciency of the model, several additional
factors were used to limit the number of included comparators:1. On the basis of results of the network meta-analysis (NMA)
conducted for this analysis, ADV was not considered a part of
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more effective and less costly [5,21].2. Because of an absence of evidence, peg-IFN α-2a plus LAM
was the only combination ﬁrst-line therapy included in
the NMA.3. Peg-IFN α-2b was not included as a comparator in the model
because there are currently no published randomized con-
trolled trials of peg-IFN α-2b compared with other therapies
included in the clinical review. Therefore, peg-IFN α-2b could
not be included in the NMA.4. Telbivudine was excluded from the model because it is not
recommended for the treatment of CHB in the United King-
dom [22].5. Emtricitabine was not included in the model because it is not
licensed for the treatment of CHB in the United Kingdom.
Nineteen clinically relevant treatment sequences were deter-
mined on the basis of these criteria. Treatment options included
peg-IFN α-2a, peg-IFN α-2a with LAM, TDF, and ETV. In those who
failed to achieve HBeAg seroconversion or viral suppression,
LAM, TDF, and ETV were included as second- and third-line
treatments. All strategies assumed that resistance or withdrawal
from third-line NA therapy was followed by best supportive care.
A full list of included and excluded treatment sequences can be
found in Appendix Tables 1 and 2 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.05.007.Treatment Effectiveness
Treatment effectiveness was evaluated in terms of different
rates of HBeAg seroconversion, undetectable HBV DNA, antiviral
resistance, treatment durability, and withdrawal because of
adverse events. It was conservatively assumed that antiviral
treatment did not affect the probability of HBsAg sero-
conversion.
The probability of achieving undetectable HBV DNA and
HBeAg seroconversion with each antiviral was based on the
NMA conducted as part of the NICE clinical guideline [5]. Four
NMAs (one per population per outcome) were conducted. Data
within each NMA were obtained by a systematic review of
MEDLINE, Embase, and the Cochrane Library from their date of
inception to October 10, 2012. Only English-language randomized
controlled trials that reported the proportion of patients who
achieved undetectable HBV DNA or HBeAg seroconversion in
treatment-naive adults were included. Undetectable HBV DNA
was deﬁned by a viral load of less than 300 copies per ml
(approximately 54 IU/ml [23]). NAs were evaluated after 48 to 52
weeks of treatment and peg-IFN α-2a at 26-week follow-up.
Treatment doses were within the therapeutic range indicated
by the British National Formulary [24]. For full methods and
results, refer to http://www.nice.org.uk/guidance/cg165/evidence/
cg165-hepatitis-b-chronic-appendices-ho2.
Based on the results of this NMA, the risk of achieving
undetectable HBV DNA and HBeAg seroconversion for each drug
relative to placebo is reported in Table 1. The probability of
achieving each outcome was calculated by applying each relative
risk to the relevant baseline transition probability (Table 1). When
two NAs were used in combination, the most effective compo-
nent was used to inform each probability. People with cirrhosis
were treated with TDF, which has been shown to be the most
effective and cost-effective drug for this condition based on
previous modeling [5]. It was assumed that previous exposure
to peg-IFN α-2a had no impact on NA efﬁcacy. In other words,
NAs were assumed to have the same effectiveness if used
following peg-IFN α-2a failure as if they were used in peg-IFN α-
2a–naive patients.The model allowed for patients to switch or add-on treatment
after the development of resistance to NAs. Rates of resistance to
each drug over 5 years were collected from published trials
(Table 2). Few studies have evaluated rates of resistance over
the longer term. In the absence of available data, resistance was
assumed to occur at a constant rate beyond 5 years. This is
consistent with assumptions made by other cost-effectiveness
studies [7,25,26]. Resistance to third-line agents resulted in a
switch to best supportive care.
In the absence of other data, estimates of serologic and
virologic treatment durability (i.e., maintenance of response)
were obtained from recent clinical practice guidelines [1,27] in
which HBeAg seroconversion was reported to be less durable
after discontinuation of NA compared with peg-IFN α-2a therapy
in HBeAg-positive CHB. In contrast, viral suppression was
reported to be more durable after discontinuing NAs than peg-
IFN α-2a in people with HBeAg-negative CHB (Table 3). It was
assumed that the probability of relapse was unrelated to the time
spent in the inactive carrier state.
NAs are generally well tolerated, with adverse-effect proﬁles
similar to that of placebo [45]. Rare instances of myopathy,
neuropathy, and pancreatitis in LAM and ETV and nephrotoxicity
to TDF have been reported. In contrast, interferons are associated
with inﬂuenza-like symptoms, depression, and anxiety. The cost
of monitoring for toxic adverse effects for each drug is described
below. It was assumed that patients who experience these
adverse effects would discontinue therapy; withdrawal rates for
each therapy are described in Table 3.Quality of Life
Most of the previously published economic evaluations of CHB
[7,16,26,46] used utility estimates from Levy et al. [47], which
were derived from 534 CHB-infected and 600 uninfected
respondents across six countries. More than 60% of the infected
respondents were from Hong Kong and China and expressed
signiﬁcantly different outcomes compared with the remaining
countries.
More recently, Woo et al. [34] elicited utilities from 400
Canadians with CHB using the standard gamble technique to
elicit values for six CHB-related health states: CHB, compensated
and decompensated cirrhosis, HCC, and liver transplantation
within and after the ﬁrst year; utilities are reported in Table 2.
These values represent a greater sample size from a more
applicable population. The impact of using utilities by Levey is
explored in sensitivity analysis.
Because we assumed that patients would immediately dis-
continue or switch drugs (and therefore recover) if they experi-
enced an adverse event, the potential impact of adverse events
on quality of life was not included in the model. The effect of this
assumption was explored in sensitivity analysis.Costs
Drug acquisition costs were obtained from the British National
Formulary [24]. Both resource use and unit costs associated with
monitoring for toxicity and response to therapy were informed by
expert opinion. Estimates of resource use associated with man-
aging patients on each drug were solicited from clinical experts.
Unit costs associated with each laboratory test, diagnostic test,
and outpatient visit were based on 2011 NHS Reference Costs [48]
and expert opinion.
If a patient received a combination of drugs, the more costly of
the two monitoring strategies was applied to account for the
maximum number of tests. The cost of managing progressive
liver disease was based on a study by Brown et al. [49] and
Table 2 – Antiviral treatment durability, adverse events, quality of life, and costs.
Model parameter Point estimate Range Source
Probability of HBeAg seroreversion in people with HBeAg-positive CHB*
Peg INF α2a 3% 2%–4% [27]
LAM and ETV 20% 15%–25% [27]
TDF and ADV 25% 20%–30% [27]
Probability of viral reactivation in people with HBeAg-negative CHB*
Peg-IFN α-2a 95% 90%–100% [1]
LAM and ETV 90% 85%–95% [27]
TDF and ADV 92% 87%–97% [27]
Withdrawal due to adverse events
Peg INF α-2a 5% 3%–6% [28–30]
LAM 5% 3%–7% [31,32]
ETV 1.5% 1%–2% [31,32]
TDF 3% 1%–5% [33]
Health state utilities
HBsAg seroconversion 0.87 0.85–0.88 [34]
Active noncirrhotic CHB 0.87 0.85–0.88 [34]
Viral suppression 0.87 0.85–0.88 Assumed equal to active CHB
Compensated cirrhosis 0.81 0.75–0.86 [34]
Decompensated cirrhosis 0.49 0.22–0.75 [34]
Hepatocellular carcinoma 0.85 0.76–0.95 [34]
Postliver transplant 0.72 0.60–0.83 [34]
Cost of antiviral drug treatment (£) (per year)
Peg INF α-2a (135 mg injection) 5,971 4,862–7,204 [24]
LAM (100 mg/d) 1, 015 829–1,224 [24]
ADV (10 mg tablet/d) 3,610 2,939–4,344 [24]
ETV (0.5 mg and 1 mg tablet/d) 4,420 3,594–5,319 [24]
TDF (245 mg tablet/d) 2,925 2,382–3,527 [24]
Cost of monitoring for toxicity and response to therapy (£) (per year)
Peg INF α-2a 832 679–1,000 See Appendix Table 1
LAM and ADV 871 871–1,057 See Appendix Table 1
TDF and ETV 876 711–1,057 See Appendix Table 1
Cost of managing liver disease due to CHB (£) (per year)
Compensated cirrhosis 2,235 1,815–2,692 [34]
Decompensated cirrhosis 8, 930 7,251–10,755 [34]
Hepatocellular carcinoma 9,427 7,667–11,346 [34]
Transplantation 47,737 38,770–57,578 [34]
First-year posttransplant 16,357 13,298–19,736 [34]
Posttransplant 10,210 8,277–12,274 [34]
All costs and probabilities were reported on an annual basis.
ADV, adefovir; CHB, chronic hepatitis B; ETV, entecavir; HBsAg, hepatitis B surface antigen; LAM, lamivudine; Peg-IFN α-2a, pegylated
interferon alpha-2a; TDF, tenofovir.
* Where a range was reported, the mean value was used to inform the point estimate. Where only a mean value was reported, a range of 10%
was assumed.
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breakdown of costs is provided in Table 2.
Uncertainty
Uncertainty surrounding the natural progression of CHB was
accounted for by assigning a probability distribution to each
parameter on the basis of point estimates and standard errors.
To preserve correlations in treatment effects, uncertainty in the
probability of response to treatment was obtained directly from
the joint posterior distributions of the Markov chain Monte-Carlo
analysis reported in WinBUGS. The model was run 1000 times,
each time randomly selecting a value for each parameter from its
respective distribution. Mean costs and QALYs were calculated by
averaging across all simulations. Average NB was also calculated
using a threshold value of £20,000 per QALY gained. The propor-
tion of model simulations in which each comparator had the
highest total NB was used to rank order the cost-effectiveness ofeach strategy and generate the cost-effectiveness frontier. Sensi-
tivity analyses were conducted to evaluate the impact of using
alternative data and assumptions on the base-case results.
Source of Financial Support
The sponsor of this study had no role in study design, data
collection, analysis, interpretation, or writing of this report. The
corresponding author had full access to all data and ﬁnal
responsibility for the decision to submit for publication.Results
Base Case
The results of the model showed that peg-IFN α-2a is the most
effective ﬁrst-line antiviral treatment for people with HBeAg-
Table 3 – Probability of antiviral resistance in NA-naive patients.
Treatment Cumulative resistance
Year 1 Year 2 Year 3 Year 4 Year 5
HBeAg-positive CHB
LAM 24.0% [35,36] 42.0% [35,36] 53.0% [35,36] 70.0% [35,36] 80.0% [35,36]
ETV 0.2% [37] 0.3% [37] 1.2% [37] NR* NR*
TDF 0.0% [33,38] 0.0% [33,38] 0.0% [33,38] NR* NR*
HBeAg-negative CHB
LAM 6.3% [39] 50.0% [40,41] 70.0% [42] 70.0% [42] NR*
ETV 0.0% [39,43] 0.0% [43] 1.2% [43] NR* NR*
TDF 0.0% [21,38,44] 0.0% [38] 0.0% [38] NR* NR*
CHB, chronic hepatitis; ETV, entecavir; HBeAg, hepatitis B e-antigen; LAM, lamivudine; NA, nucleos(t)ide analogues; NR, not reported; TDF,
tenofovir.
* Where data were not identiﬁed in the literature, the probability from the previous year was applied.
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HBeAg seroconversion or viral suppression, peg-IFN α-2a - TDF
- TDF þ LAM is the most effective sequence for people with
HBeAg-positive CHB, with a cost of £7488 per QALY gained
compared with no treatment. In those with HBeAg-negative
CHB, peg-IFN α-2a- ETV- TDF is the most effective sequence,
with a cost of £6981 per QALY gained compared with no
treatment.
The NB framework allows us to rearrange the decision rule by
calculating the probability that each strategy will have the
greatest overall beneﬁt at different threshold values. It provides
a method for rank-ordering interventions by eliminating the need
to consider dominance and calculate incremental cost-
effectiveness ratios. Under this framework, we see that there is a
high degree of uncertainty as to whether peg-IFN α-2a should be
administered alone or in combination with LAM and whether ETV
or TDF represents the most cost-effective second-line antiviral
therapy. Table 4 presents total costs and QALYs for the ﬁve
most cost-effective strategies for each population, ranked accord-
ing to maximum expected NB, and Figure 2 shows the probabilityTable 4 – Probabilistic results of base-case analysis.
Strategy Total
cost (£)
Total
QALYs
HBeAg-positive CHB
No treatment 32,754 14.618
Peg-IFN α-2a - TDF - TDF þ LAM 45,794 16.359
Peg-IFN α-2a þ LAM - TDF - TDF
þ LAM
46,495 16.351 D
Peg-IFN α-2a - TDF - ETV 46,856 16.358 D
Peg-IFN α-2a - ETV - TDF 47,547 16.355 D
Peg-IFN α-2a þ LAM - TDF - ETV 47,680 16.349 D
HBeAg-negative CHB
No treatment 50, 388 12.18
Peg-IFN α-2a - ETV - TDF 60, 241 13. 59
Peg-IFN α-2a þ LAM - ETV - TDF 60,848 13.60
Peg-IFN α-2a - TDF - TDF þ LAM 61,493 13.59
Peg-IFN α-2a þ LAM - TDF - TDF
þ LAM
62,106 13.60
Peg-IFN α-2a - TDF - ETV 63,202 13.59
-, indicates; CE, cost-effective; ETV, entecavir; ICER, incremental cost-ef
IFN α-2a, pegylated interferon alpha-2a; QALY, quality-adjusted life-year
* Compared with the next most effective strategy, less effective and mo
† At a threshold of 20,000 per QALY gained.that the optimal option would be cost-effective at different
thresholds.Sensitivity Analyses
Threshold analyses showed that following initial peg-IFN α-2a
therapy, ETV was the most cost-effective NA for HBeAg-positive
patients when the cost of therapy was less than £3912 per year. In
a separate analysis, ETV was also found to be more cost-effective
than TDF at an increased rate of HBeAg seroconversion in HBeAg-
positive patients. In HBeAg-negative patients, TDF followed by
ETV was the most cost-effective NA following peg-IFN α-2a when
the annual cost of ETV was less than £2936.
Limited data exist regarding the off-treatment durability of
NAs; that is, the maintenance of response after discontinuation
of treatment. In sensitivity analysis, we found that the conclu-
sions of the analysis were unchanged if we assumed that
serologic durability did not differ by drug class.
Prolonged use of TDF has been reported to lead to reduced
bone mineral density in patients with comorbid HIV [50].ICER* NMB
(£)†
NMB rank
(max – min)
Probability most
CE (%)
Baseline 259,606 18 1
£7488 281,395 1 (6 – 1) 79
ominated 280,523 2 (7 – 1) 18
ominated 280,303 3 (7 – 2) 0
ominated 279,554 4 (8 – 2) 1
ominated 279,292 5 (10 – 2) 0
Baseline 193,198 18 (19 – 1) 11
£6981 211,571 1 (14 – 1) 45
£4577 211,103 2 (14 – 1) 21
£4524 210,383 3 (15 – 1) 13
£4566 209,913 4 (15 – 1) 9
£4,650 208,631 5 (16 – 2) 0
fectiveness ratio; LAM, lamivudine; NMB, net monetary beneﬁt; Peg-
; TDF, tenofovir.
re expensive interventions are said to be “dominated.”
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and patients are currently not routinely monitored. The model
revealed that adding the cost of bone density testing to the cost of
TDF monitoring did not change the conclusions of the analysis.
Few trials have evaluated the effectiveness of combination
antiviral therapies. Reducing the effectiveness of TDF by half
when administered in combination did not alter the conclusions
of the model.
The results of the model were not affected by an increased
rate of withdrawal due to adverse events associated with peg-IFN
α-2a or a decrease in utility (of 0.01–0.10) for patients treated with
peg-IFN α-2a.
On substituting the utility values fromWoo et al. [34] with those
from Levy et al. [47], we found that these values did not change the
conclusions of the analysis. Because of the high probability of LAM
resistance, clinical experts of the GDG did not think that adding
LAM to peg-IFN α-2a or TDF was likely to be of value in the HBeAg-
positive population (see Appendix Table 6 in Supplemental Materi-
als found at http://dx.doi.org/10.1016/j.jval.2015.05.007).Discussion
We developed a probabilistic Markov model with a lifetime
horizon for the economic evaluation of relevant combinations
and sequences of drugs for the treatment of HBeAg-positive and
HBeAg-negative CHB. The model was developed as part of the
2013 NICE guideline on the diagnosis and management of CHB
[5]. Model parameters were based on best available data regard-
ing the natural history of CHB, efﬁcacy and tolerability of treat-
ments, incidence of antiviral resistance, and durability of
response. Costs were measured from a UK NHS perspective,
and beneﬁts were measured in terms of QALYs.
Our ﬁndings show that peg-IFN α-2a is the most cost-effective
ﬁrst-line antiviral treatment for people with CHB. In those
who fail to achieve HBeAg seroconversion or viral suppression,
TDF is the most effective and cost-effective second-line therapy
for people with HBeAg-positive CHB, whereas ETV is the
most effective and cost-effective second-line therapy for
HBeAg-negative patients. Because the incremental cost-
effectiveness ratio of each strategy falls well below NICE’s
£20,000 to £30,000 threshold, these strategies are likely to be
considered cost-effective by UK policymakers. The results of this
analysis were used to inform recommendations within the
guideline [5].
Probabilistic sensitivity analysis revealed TDF to be the optimal
NA in 97% of the simulations in the HBeAg-positive population
that has failed treatment with peg-IFN α-2a. There was greater
uncertainty in the HBeAg-negative population, in which ETV had a
66% probability of being the optimal NA after peg-IFN α-2a. This
ﬁnding adds clarity to previously published cost-utility evaluations
that have reported a high degree of uncertainty in the relative
cost-effectiveness of TDF and ETV across both populations [4].
Results were robust to most of the sensitivity analyses.
Although sensitive to the price of ETV, the cost required to result
in a change in strategy was below the lower bound of our estimated
range. The model was also sensitive to HBeAg seroconversion
rates. Because raised alanine aminotransferase level is associated
with higher rates of seroconversion, ETV may be the most cost-
effective second-line therapy in HBeAg-positive patients with
elevated alanine aminotransferase levels. In the base-case analysis,
the addition of LAM to peg-IFN α-2a was associated with increased
costs compared with peg-IFN α-2a alone, but there was uncertainty
regarding its impact on effectiveness. As a result, peg-IFN α-2a
alone was found to be the more cost-effective choice. ADV and LAM
were not included as ﬁrst-line treatment options because both areless effective and ADV is more expensive than TDF and ETV [5];
their inclusion would not change the results of the analysis.
Many studies have evaluated the cost-utility of antiviral thera-
pies for the treatment of CHB; however, none has been as
exhaustive in their inclusion of comparators as the one presented
here. This is a critical difference, because the results of
other analyses are conﬂicting and suggest that results are sensitive
to the choice of comparators, clinical inputs, and assumptions
regarding gaps in the evidence, particularly around drug resistance.
Jones et al. [51] found that peg-IFN α-2a was more cost-effective
than NA as a ﬁrst-line treatment, though they did not include ETV
or TDF. Two studies [4,7] found that regardless of HBeAg status,
TDF was the most cost-effective ﬁrst-line treatment, though they
did not include peg-IFN α2a in their analyses. Earlier studies
[16,46,52,53] found that ETV was most cost-effective, but only
one of these analyses included peg-IFN α-2a [46] and none
included TDF.
It is also the ﬁrst to allow for transitions from HBeAg-positive
to HBeAg-negative CHB and account for differences in the cost of
monitoring according to the known adverse-effect proﬁle of each
drug class. Estimates of HBeAg seroconversion and HBV DNA
suppression were obtained from the most recent available NMA,
which is the only analysis to include trials of TDF conducted in
people with CHB. We believe our model represents the most
comprehensive representation of the disease process and treat-
ment effectiveness to date.
In common with other models, ours is limited by a lack of long-
term evidence of efﬁcacy, resistance, and off-treatment durability
(i.e., maintenance of response after discontinuation of treatment).
In addition, few trials have evaluated the effectiveness of sequen-
tial treatment strategies in patients who develop resistance to the
initial NA, the effectiveness and safety of most of the antiviral
combinations, or on-treatment rates of HBsAg seroconversion.
Historically, NAs have been the most common ﬁrst-line treat-
ment for CHB due to relatively few adverse events compared with
interferon. Previous evaluations of NAs assumed that adverse effects
do not differ and have no effect on costs or quality of life [7,16,25,26],
nor did they differentiate the cost of monitoring for toxicity between
drugs [7,25,26,46,54]. The only previously published study to com-
pare NAs with peg-IFN α-2a assumed that inﬂuenza-like symptoms
would be treated by over-the-counter drugs and depression would
be treated with 6 months of antidepressant medication at an
average additional cost of $22 per patient [46]. Whether interferon
has an adverse impact on quality of life compared with NAs has not
been well studied, but sensitivity analysis showed that the model
was not sensitive to any of these assumptions.
There remain many unanswered questions as a result of the
relatively recent approval of these drugs for the treatment of
CHB. Future clinical trials and long-term follow-up studies should
include HBsAg seroconversion and off-treatment durability as out-
comes because they represent the ultimate goal of therapy [55].
Deﬁnitive resistance to TDF has not been substantiated, but is a
possibility. It is important to know whether resistance to ETV will
increase over time and if combination therapy represents a long-
term solution to the development of cross-resistance in patients
with high levels of viremia. Prospective studies designed to capture
the incidence of renal toxicity and changes in bone mineral density
are also needed [50]. Finally, additional research to inform
estimates of disutility associated with interferon treatment may be
needed, though the model was not sensitive to variation in this
parameter.
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